nutrients-logo

Journal Browser

Journal Browser

Nutritional Treatment and Screening for Inherited Metabolic Diseases

A special issue of Nutrients (ISSN 2072-6643). This special issue belongs to the section "Nutrition and Metabolism".

Deadline for manuscript submissions: 25 October 2025 | Viewed by 574

Special Issue Editors


E-Mail Website
Guest Editor
Centro de Referencia Nacional (CSUR) y Europeo (MetabERN) para Enfermedades Metabólicas Hereditarias, Unidad de Enfermedades Mitocondriales-Metabólicas Hereditarias, Servicio de Pediatría, Instituto de Investigación i+12, CIBERER-U723, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain
Interests: newborn; metabolic diseases; urea cycle disorders; newborn screening; nutritional treatment
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Centro de Referencia Nacional (CSUR) y Europeo (MetabERN) para Enfermedades Metabólicas Hereditarias, Unidad de Enfermedades Mitocondriales-Metabólicas Hereditarias, Servicio de Pediatría, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain
Interests: hereditary metabolic diseases; mitochondrial diseases; newborn screening; nutritional treatment
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Centro de Referencia Nacional (CSUR) y Europeo (MetabERN) para Enfermedades Metabólicas Hereditarias, Unidad de Enfermedades Mitocondriales-Metabólicas Hereditarias, Servicio de Pediatría, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain
Interests: hereditary diseases; inborn errors of metabolism; newborn screening; early identification and therapy; nutritional treatment
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Inherited metabolic diseases (IMDs), also known as inborn errors of metabolism, are a group of genetic disorders caused by pathogenic variants affecting specific metabolic enzymes or pathways. Although individually rare, they collectively have a significant impact on global morbidity and mortality.

IMDs typically result in the accumulation of toxic metabolites or a deficiency of essential biochemical products, disrupting cellular function and energy production. Given the fundamental role of metabolism in all organ systems, these disorders often lead to severe multisystem manifestations if untreated.

Advances in newborn screening have improved early diagnosis, enabling timely interventions. Treatment varies depending on the specific metabolic defect and may include dietary modifications, cofactor supplementation, enzyme replacement therapy, or, in severe cases, organ or stem cell transplantation. Emerging research is increasingly focused on gene therapy as a potential curative approach.

This Special Issue, “Nutritional Treatment and Screening for Inherited Metabolic Diseases”, aims to highlight the latest research in this field, and we welcome original articles, case reports, experimental studies, and reviews.

Dr. Elena Martín-Hernández
Dr. Marcello Bellusci
Dr. Pilar Quijada-Fraile
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Nutrients is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • inherited metabolic diseases
  • inborn errors of metabolism
  • newborn screening
  • nutritional treatment for inherited metabolic diseases
  • enzymatic treatment
  • gene therapy
  • liver transplant

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

20 pages, 821 KiB  
Article
Understanding the Natural History and the Effects of Current Therapeutic Strategies on Urea Cycle Disorders: Insights from the UCD Spanish Registry
by Elena Martín-Hernández, Marcello Bellusci, Patricia Pérez-Mohand, Patricia Correcher Medina, Javier Blasco-Alonso, Ana Morais-López, Javier de las Heras, Silvia María Meavilla Olivas, Lucy Dougherty-de Miguel, Maria Luz Couce, Elvira Cañedo Villarroya, María Concepción García Jiménez, Pedro Juan Moreno-Lozano, Inmaculada Vives, Mercedes Gil-Campos, Sinziana Stanescu, Leticia Ceberio-Hualde, María Camprodón, Elisenda Cortès-Saladelafont, Rafael López-Urdiales, Mercedes Murray Hurtado, Ana María Márquez Armenteros, Concha Sierra Córcoles, Luis Peña-Quintana, Mónica Ruiz-Pons, Carlos Alcalde, Fernando Castellanos-Pinedo, Elena Dios, Delia Barrio-Carreras, María Martín-Cazaña, Mónica García-Peris, José David Andrade, Camila García-Volpe, Mariela de los Santos, Angels García-Cazorla, Mireia del Toro, Ana Felipe-Rucián, María José Comino Monroy, Paula Sánchez-Pintos, Ana Matas, David Gil Ortega, Álvaro Martín-Rivada, Ana Bergua, Amaya Belanger-Quintana, Isidro Vitoria, Raquel Yahyaoui, Belén Pérez, Montserrat Morales-Conejo and Pilar Quijada-Fraileadd Show full author list remove Hide full author list
Nutrients 2025, 17(7), 1173; https://doi.org/10.3390/nu17071173 - 28 Mar 2025
Viewed by 472
Abstract
Background/Objectives: The present study updates the Spanish registry of patients with urea cycle disorders (UCD), originally established in 2013, to provide comprehensive epidemiological data and evaluate the impact of therapeutic strategies and newborn screening (NBS) on clinical outcomes. Methods: This retrospective, [...] Read more.
Background/Objectives: The present study updates the Spanish registry of patients with urea cycle disorders (UCD), originally established in 2013, to provide comprehensive epidemiological data and evaluate the impact of therapeutic strategies and newborn screening (NBS) on clinical outcomes. Methods: This retrospective, multicenter study focuses on 255 Spanish UCD patients. It includes all living and deceased cases up to February 2024, analyzing demographic, clinical, and biochemical variables. Results: The incidence of UCD in Spain over the past decade was 1:36,063 births. The most common defects were ornithine transcarbamylase deficiency (OTCD) and argininosuccinate synthetase deficiency. Early-onset (EO) cases comprised 32.7%, and 10.6% were diagnosed through NBS. Global mortality was 14.9%, higher in carbamoylphosphate synthetase 1 deficiency (36.8%) and male OTCD patients (32.1%) compared to other defects (p = 0.013). EO cases presented a higher mortality rate (35.8%) than late-onset (LO) cases (7.1%) (p < 0.0001). The median ammonia level in deceased patients was higher at 1058 µmol/L (IQR 410–1793) than in survivors at 294 µmol/L (IQR 71–494) (p < 0.0001). Diagnosis through NBS improved survival and reduced neurological impairment compared to symptomatic diagnosis. Neurological impairment occurred in 44% of patients, with worse neurological outcomes observed in patients with argininosuccinate lyase deficiency, arginase 1 deficiency, hyperornithinemia-hyperammonemia-homocitrullinuria, EO presentations, pre-2014 diagnosis, and patients with higher levels of ammonia at diagnosis. Among transplanted patients (20.6%), survival was 95.2%, with no significant neurological differences compared to non-transplanted patients. Conclusions: This updated analysis highlights the positive impact of NBS and advanced treatments on mortality and neurologic outcomes. Persistent neurological challenges underscore the need for further therapeutic strategies. Full article
(This article belongs to the Special Issue Nutritional Treatment and Screening for Inherited Metabolic Diseases)
Show Figures

Figure 1

Back to TopTop